Hypoxia-abled biomarkers could be a boon for prostate cancer imaging

August 1, 2013

The gastrin-releasing peptide receptor (BB2r) has become a popular target in prostate cancer imaging, but low local retention of tracers at the tumor site impedes imaging. Hypoxia-enhanced targeting of these receptors may be just what the doctor ordered for better tumor-tracer retention, according to a study published July 29 th in the Journal of Nuclear Medicine .

Zhengyuan Zhou, a researcher and PhD candidate in the department of Pharmaceutical Sciences and College of Pharmacy at the University of Nebraska Medical Center in Omaha, Neb., and colleagues conducted the first study of in vivo hypoxia-enhanced BB2-r targeted tracers in mice and found that the inclusion of 2-nitroimidazole moieties showed better local tumor affinity with I-111 bombesin and could potentially be investigated with other agents to improve BB2r targeting of prostate tumors.